Zimmer Biomet to Acquire iovera° from Pacira in $350 Million Deal
1h ago|3 min readQuick Read
Fazen Markets Editorial Desk
Collective editorial team · methodology
medical-devicesmergers-and-acquisitions
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Pacira BioSciences announced on June 30, 2026, that it has entered a definitive agreement to sell its iovera° cryoanalgesia business to Zimmer Biomet Holdings for $350 million in cash. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions and regulatory approvals. The divestiture will allow Pacira to focus on its core non-opioid pain management portfolio, while Zimmer gains a complementary platform for its sports medicine and orthopedic surgery segments.
The transaction follows a two-year period of strategic portfolio reviews across the medical device sector, with large-cap names shedding non-core assets. In March 2025, Johnson & Johnson completed the $1.1 billion divestiture of its Kyocera Medical joint venture to focus on higher-margin surgical robotics. The current deal occurs against a backdrop of rising interest in outpatient surgical solutions, with the Federal Reserve's benchmark rate at 4.63%. The immediate catalyst for Pacira was likely pressure to improve its balance sheet use after a period of increased R&D spending. Zimmer Biomet, with a stronger cash position, identified iovera°'s nerve-freezing technology as a logical adjacency to its existing knee and shoulder repair systems used in ambulatory surgery centers.
The $350 million all-cash purchase price represents approximately 2.3x iovera°'s estimated 2025 revenue of $152 million. Pacira BioSciences' market capitalization prior to the announcement was $2.1 billion. iovera° revenue grew by 18% year-over-year in 2025, outpacing the broader US pain management device market's 7% growth. Zimmer Biomet reported a cash balance of $2.4 billion as of its last quarterly filing, indicating the acquisition will consume about 15% of its available cash. The deal's valuation multiple is below the sector's 3.8x median for medical device acquisitions over $250 million in the past 24 months. Pacira's shares gained 4.2% in pre-market trading following the news, while Zimmer's shares were down 0.8%.
| Metric | Pacira (PCRX) | Zimmer Biomet (ZBH) |
|---|---|---|
| Market Cap | $2.1B | $28.5B |
| Deal Value | $350M | $350M |
| Cash Used | N/A (Seller) | 15% of available cash |
Second-order effects include a potential boost for other companies focused on non-opioid pain relief, such as Nevro Corp and Avanos Medical, as the deal validates the market. The transaction is a direct negative for competitive cryoanalgesia systems, including those from Myoscience, which now faces a larger, integrated competitor. Within the orthopedic sector, Stryker Corporation may face increased competition for ambulatory surgery center contracts. A key limitation is that the $350 million price tag is relatively small for Zimmer, representing just over 1% of its market cap, limiting its immediate financial impact. Positioning data from the options market shows elevated call volume for Pacira, suggesting traders expect the capital to be used for share repurchases or debt reduction, while Zimmer's flow remains neutral.
Investors should monitor Pacira's Q2 2026 earnings call, scheduled for late July, for details on the use of proceeds and any updated full-year guidance excluding iovera°. Zimmer Biomet's next quarterly report will provide integration plans and overlap targets. A key catalyst is regulatory approval from the Federal Trade Commission, with a decision expected by late Q3 2026. Levels to watch include Pacira's stock support at $38.50, its level prior to the announcement, and resistance at $45. If Zimmer's stock sustains a decline below its 200-day moving average of $125.70, it may signal investor concern over strategic focus versus accretion.
Pacira investors receive a $350 million cash infusion, which the company stated will be used to pay down debt and support its flagship EXPAREL franchise. This deleveraging improves the balance sheet and focuses the company on its higher-margin, longer-duration non-opioid analgesic platform. The sale removes a capital-intensive business unit, potentially improving Pacira's operating margin profile by 150-200 basis points over the next year.
Historically, Zimmer has integrated acquisitions by folding them into existing commercial sales channels, particularly its large sports medicine and extremities divisions. The iovera° system, used for knee osteoarthritis pain, aligns directly with Zimmer's existing knee implant and repair salesforce. Past integrations, like the 2021 acquisition of A&E Medical, saw cost synergies realized within 18 months through combined distribution.
Cryoanalgesia is a non-drug, non-opioid therapy that uses precise cold to ablate peripheral nerves, blocking pain signals for months. The global market for cryoanalgesia devices was estimated at $580 million in 2025 and is projected to grow at a 12% compound annual rate through 2030, driven by the shift to outpatient surgery and the opioid-sparing mandate. The technology is primarily used in orthopedic, podiatric, and chronic pain procedures.
The deal strategically refocuses Pacira on its core pharmaceutical business while giving Zimmer an immediate growth asset in the expanding ambulatory pain market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.